Please go to the PowerPak homepage
and select a course.
Testing to Target Non-Small Cell Lung Cancer: Managed Care Perspectives
Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from AstraZeneca.
Recent advancements in the scientific knowledge of non-small cell lung cancer (NSCLC) pathology have shifted the paradigm of care from a "one-size fits all" regimen, to one that focuses on individualized therapy and integrating biomarker-targeted therapies into treatment paradigms. The number of approved and emerging NSCLC targeted therapies tops a dozen. These new cancer agents contribute substantially to improved outcomes for patients as well as rising healthcare costs. Experts indicate that the key to providing cost-effective care is to better match patients with specifically targeted treatment options.
This archived webcast will highlight the latest clinical evidence about the role of genetic and molecular targets in developing personalized treatment plans for patients with NSCLC, with a special focus on opportunities for managed care and specialty pharmacists to facilitate individualized care. Expert faculty offer insights on evolving best practices for biomarker testing and interpretation to optimize therapy choice, recent data from the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, and the pharmacoeconomic implications of biomarker-directed NSCLC management.
Managed care and specialty pharmacists will gain new skills in assessing biomarker results and developing treatment plans based on the presence of drug-actionable targets in NSCLC, as well as new strategies for supporting the safe, effective, and evidence-based use of targeted therapies, thus optimizing pharmaceutical care.
This activity is designed for managed care and specialty pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:
- ASSESS the role of genetic and molecular biomarkers in guiding NSCLC treatment plans.
- EVALUATE the safety, efficacy, and therapeutic role of new and emerging targeted therapies.
- RECOMMEND pharmacy-driven strategies to facilitate individualized NSCLC management.
CREDIT DESIGNATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-16-212-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.
NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.
Please allow up to 30 days for your credit to appear on CPE Monitor.
Type of Activity: Application
Published: October 6, 2016
Expires: October 6, 2017
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes
HOW TO EARN CREDIT
Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.
FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:
R. Donald Harvey, PharmD, FCCP, BCOP (Course Director)
Associate Professor, Hematology/Medical Oncology
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Dr Harvey reports receiving grants/research support from and serving on the advisory board for Bristol-Myers Squibb Company, Baxter International Inc, and Takeda Pharmaceuticals USA Inc; and serving as a consultant for Amgen/Onyx and Idec. Dr Harvey also reports his spouse receiving grants/research support from Baxalta and Novo Nordisk and serving as a consultant for Baxalta, Biogen, and Idec.
Matthew Farber, MA
Oncology Disease State
Walgreens Specialty Pharmacy
Mr Farber reports holding stock in Walgreen's Boots Alliance.
OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at email@example.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
The following is an archived webcast designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, an archived webcast, and a CPE postassessment, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5
TABLE OF CONTENTS
Welcome and Webcast Goals
R. Donald Harvey, PharmD, FCCP, BCOP
State of the Science: Overview of NSCLC in 2016
R. Donald Harvey, PharmD, FCCP, BCOP
Recent Updates on NSCLC Targets and Targeted Therapies: New Opportunities for Personalized Treatment
R. Donald Harvey, PharmD, FCCP, BCOP
Providing Individualized Care for Patients with NSCLC: Pharmacist Perspectives
Matthew Farber, MA
Question & Answer Session
R. Donald Harvey, PharmD, FCCP, BCOP, and Matthew Farber, MA
Postassessment and Evaluation
What you are about to see is a previously recorded live webcast. Please note that only "home study" credit will be awarded for participating in this archived presentation.
No "live" credits are available.